Compare · BYRN vs TMO
BYRN vs TMO
Side-by-side comparison of Byrna Technologies Inc. (BYRN) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- BYRN operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $179.14B, about 1259.4x BYRN ($142.2M).
- Over the past year, BYRN is down 78.2% and TMO is up 16.3% - TMO leads by 94.6 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 1 for BYRN).
- TMO has more recent analyst coverage (25 ratings vs 10 for BYRN).
- Company
- Byrna Technologies Inc.
- Thermo Fisher Scientific Inc
- Price
- $6.27-0.16%
- $482.27-2.41%
- Market cap
- $142.2M
- $179.14B
- 1M return
- +21.98%
- +6.57%
- 1Y return
- -78.24%
- +16.34%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 17
- Recent ratings
- 10
- 25
Byrna Technologies Inc.
Byrna Technologies Inc., a less-lethal defense technology company, develops and manufactures less-lethal munitions. The company offers a Byrna line of handheld personal security devices, including the Byrna HD, a .68 caliber handheld personal security device that is designed to be used by civilians and private security professionals, as well as Byrna HD magazines, launchers, and projectiles. It operates in the United States, Canada, and South Africa. The company was formerly known as Security Devices International, Inc. and changed its name to Byrna Technologies Inc. in March 2020. Byrna Technologies Inc. was incorporated in 2005 and is headquartered in Andover, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest BYRN
- Byrna Technologies Launches Media Partnership with Fox Sports Through iHeartMedia to Expand National Reach
- Byrna Technologies Sets Upcoming Investor Conference Schedule
- Chief Financial Officer Kearnes Laurilee converted options into 2,313 shares, increasing direct ownership by 33% to 9,387 units (SEC Form 4)
- Amendment: SEC Form 4 filed by Ganz Bryan
- SEC Form SCHEDULE 13G filed by Byrna Technologies Inc.
- SEC Form 4 filed by Ganz Bryan
- Byrna Technologies Promotes Matthew Campagni to Chief Strategy Officer
- Byrna Technologies downgraded by Craig Hallum with a new price target
- Byrna Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Byrna Technologies Inc.
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)